Is There a Need for Cluster Hepatitis B and C Epidemiological Studies in the Region?: Yes

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. 1.
   Van Damme P, Van Herck K, Michielsen P, Francque S, Shouval D. Chronic Hepatitis and other Liver Disease. In: Detels R, Beaglehole R, Lansang MA, Gulliford M, editors. Oxford Textbook of Public Health. Fifth Ed. Oxford Univ.Press, 2011, pp. 1248–63.Google Scholar
2. 2.
   •• Kershenobich D, Razavi HA, Avila JFS, Bessone F, Coelho HS, Dagher L, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int. 2011;31(S2):18–29. Provides an exhaustive review of available evidence on Hepatitis C in LAC. The article has related contents in all supplement.PubMedCrossRefGoogle Scholar
3. 3.
   Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–15.PubMedCrossRefGoogle Scholar
4. 4.
   •• Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42. The article provides systematic revision of global hepatitis C virus infection, with primary data synthesis.PubMedCrossRefGoogle Scholar
5. 5.
   Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.PubMedGoogle Scholar
6. 6.
   Shepard CU, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.PubMedCrossRefGoogle Scholar
7. 7.
   Méndez-Sánchez N, Gutiérrez-Grobe Y, Kobashi-Margáin RA. Epidemiology of HCV infection in Latin America. Ann Hepatol. 2010;9(Suppl):27–9.PubMedGoogle Scholar
8. 8.
   Szabo SM, Bibby M, Yuan Y, Donato BM, Jimenez-Mendez R, Castañeda-Hernandez G, et al. The epidemiologic burden of hepatitis C virus infection in Latin America. Ann Hepatol. 2012;11(5):623–35.PubMedGoogle Scholar
9. 9.
   Silveira TR et al. Hepatitis B seroprevalence in Latin America. Rev Panam Salud Publica [online]. 1999;6(6):378–83.Google Scholar
10. 10.
    Tanaka J. Hepatitis B, epidemiology in Latin America. Vaccine. 2000;18:S17–9.PubMedCrossRefGoogle Scholar
11. 11.
    Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14(1):1–21.PubMedCrossRefGoogle Scholar
12. 12.
    •• Lozano J et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128. Landmark article of an international collaboration on the global burden of disease study, updated up to 2010. Best estimates of burden. The contribution of hepatitis was updated and modeled to fit into GBD study. Several articles of this series provide data on disability and risk factor contribution. Interactive tables provided. Should be read with companion articles.PubMedCrossRefGoogle Scholar
13. 13.
    World Gastroenterology Organization Global Guidelines: Diagnosis, management and prevention of hepatitis C. April 2013, at:(http://www.worldgastroenterology.org/assets/export/userfiles/WGO_Hepatitis%20C_Final%20Version.pdf).
14. 14.
    •• Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, et al. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int. 2011;31 suppl 2:4–17. One among several models addressing the systems context of hepatitis C virus.PubMedCrossRefGoogle Scholar
15. 15.
    Berwick DM. Disseminating innovations in health care. JAMA. 2003;289(15):1969–75.PubMedCrossRefGoogle Scholar
16. 16.
    CDC. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. MMWR Recommendations and Reports. August 17, 2012 / 61(RR04);1–18.Google Scholar
17. 17.
    Last JM. Dictionary of Epidemiology. IEA. 2001.Google Scholar
18. 18.
    Kogevinas M, Chatzi L. Cross-sectional studies. In: Detels R, Beaglehole R, Lansang MA, Gulliford M, editors. Oxford Textbook of Public Health. Fifth Ed. Oxford Univ.Press, 2011, pp. 472–83.Google Scholar
19. 19.
    Zochetti C, Consonni D, Bertazzi PA. Relationship between prevalence rate ratios in cross-sectional studies. Int J Epidemiol. 1997;26:220–3.CrossRefGoogle Scholar
20. 20.
    Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: a systematic review. Intervirology. 2007;50:1–8.PubMedCrossRefGoogle Scholar
21. 21.
    Valdespino JL, Conde-Gonzalez CJ, Olaiz-Fernandez G, Palma O, Kershenobich D, Sepulvida J. Seroprevalencia de la hepatitis C en adultos de México: un problema de salud pública emergente. Sal Pub Mex. 2007;49:S395–403.CrossRefGoogle Scholar
22. 22.
    •• Pereira LM, Martelli CM, Moreira RC, Merchan-Hamman E, Stein AT, Cardoso MR, et al. Prevalence and risk factors of Hepatitis C virus infection in Brazil, 2005 through 2009: a cross-sectional study. BMC Infect Dis. 2013;13:60. Latest and largest national prevalence study from Brazil. Several insights of hepatitis C risk factors less well addressed before. Important due to results, size and methods.PubMedCrossRefGoogle Scholar
23. 23.
    Tolonen H, Dobson A, Kulathinal S, Sangita A, for the WHO MONICA Project. Assessing the quality of risk factor survey data: lessons from the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil. 2006;13:104–14.PubMedCrossRefGoogle Scholar
24. 24.
    Brownson R. Outbreak and cluster investigations. In: Brownson RC, Petiti DB. Applied epidemiology: From theory to practice. Oxford Univ.Press, 1998. p. 71–103.Google Scholar
25. 25.
    Wasley A, Alter M. Epidemiology of hepatitis C: geographic differences and temporal trends. Sem Liver Dis. 2000;20:1–16.CrossRefGoogle Scholar
26. 26.
    Aday ML. Designing and conducting health surveys. 2nd Ed. Jossey-Bass,1996. pp. 120–1.Google Scholar
27. 27.
    • Ximenes, Ricardo Arraes de Alencar, et al. Methodology of a nationwide cross-sectional survey of prevalence and epidemiological patterns of hepatitis A, B and C infection in Brazil. Cad. Saúde Pública [online]. 2010;26(9):1693–704. ISSN 0102-311X. Living example on methods for cross-sectional studies in Brazil. Google Scholar
28. 28.
    El-Sayed et al. Social network analysis and agent based modeling in social epidemiology. Epidemiol Perspect Innov. 2012;9:1.PubMedCrossRefGoogle Scholar
29. 29.
    Marmot M. Multi level approaches to understanding social determinants of health. In: Berkman LF, Kawachi I, editors. Social Epidemiology. Oxford UniversityPress; p. 349–367Google Scholar
30. 30.
    Seef LB. The history of the“natural history”of hepatitis C (1968–2009). Liver Int. 2009;29(s1):89–99.CrossRefGoogle Scholar
31. 31.
    Mathers CD, Ezzati M, Lopez AD, Murray CJL, Rodgers A. Causal decomposition of summary measures of population health. In: Murray CL, Salomon JA, Mathers CD, Lopez A. Summary measures of population health. WHO; 2006. pp. 274–90.Google Scholar
32. 32.
    Nurminen M, Nurminen T, Corvalan CF. Methodologic issues in epidemiologic risk assessment. Epidemiology. 1999;10:585–93.PubMedCrossRefGoogle Scholar
33. 33.
    Samet JA, Muñoz A. The evolution of the cohort study. Epidemiol Rev. 1998;20:1–14.PubMedCrossRefGoogle Scholar
34. 34.
    Mulassi AH, Borracci RA, Calderón JGE, Vinay P, Mulassi M. Social networks on smoking, alcohol use and obesity among adolescents attending a school in the city of Lobos, Buenos Aires. Arch Argent Pediatr. 2012;110(6):474–84.PubMedGoogle Scholar
35. 35.
    Ties Boerma J, Weir SS. Integrating Demographic and Epidemiological Approaches to Research on HIV/AIDS: The Proximate-Determinants Framework. J Infect Dis. 2005;191(Supplement 1):S61–7. doi: 10.1086/425282.PubMedCrossRefGoogle Scholar
36. 36.
    Romano CM, de Carvalho-Mello IMVG, Jamal LF, de Melo FL, Iamarino A, et al. Social networks shape the transmission dynamics of hepatitis C virus. PLoS ONE. 2010;5(6):e11170. doi: 10.1371/journal.pone.0011170.PubMedCrossRefGoogle Scholar
37. 37.
    Hulka B, Wheat J. Patterns of utilization: the patient perspective. Med Care. 1985;23(5):438–60.PubMedCrossRefGoogle Scholar
38. 38.
    Insua JT. The ecology of medical care in poor settings: Self reported health care utilization in Santiago Del Estero; Argentina. ISPOR 4th Latin America Conference, 2013, Buenos Aires, Argentina.Google Scholar
39. 39.
    Insua JT, Villalon R. 30 day and one year hospital re-admissions in Argentina: Burden, mortality and cost. Evidence from a Multicenter Study of a Transitional Country. ISQua, Edinburgh, 2013. (abstr ID).Google Scholar
40. 40.
    Barreto SM, Miranda JJ, Figueroa JP, Schmidt MI, Munoz S, Kuri-Morales PP, et al. Epidemiology in Latin America and the Caribbean: current situation and challenges. Int J Epidemiol. 2012;41:557–71.PubMedCrossRefGoogle Scholar
41. 41.
    Insua JT, O’Flaherty M, Frontera Vacca MJ, et al. HCV infection (HCVI) prevalence in Argentine and impact of unsafe health care parenteral practices (HC-UPP): a seroprevalence survey. Journal of General Internal Medicine, 2005 (Suppl. 2): 185. (Abstract).Google Scholar
42. 42.
    March D, Susser E. The eco- in eco-epidemiology. Int J Epidemiol. 2006;35:1379–83.PubMedCrossRefGoogle Scholar
43. 43.
    Latin America: Gini back in the bottle: An unequal continent is becoming less so. The Economist, Oct 13th 2012.Google Scholar
44. 44.
    Spasoff RA. Epidemiologic Methods for Health Policy. Oxford Univ.Press; 1999. pp. 105–14.Google Scholar
45. 45.
    Global Forum For Health Research: http://www.globalforumhealth.org/about/1090-gap/.
46. 46.
    Global Forum for Health Research. The 10/90 report on health research 2000. Geneva: World Health Organization; 2000.Google Scholar
47. 47.
    Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. Priorities in health. Disease Control Priorities Project. Washington (DC):2006.Google Scholar
48. 48.
    Lee K, Mills A. Strengthening governance for global health research. BMJ. 2000;321(7264):775–6.PubMedCrossRefGoogle Scholar
49. 49.
    WHO. Assessing and tackling patient harm. A methodological guide for data-poor hospitals. Geneva, 2010.Google Scholar
50. 50.
    Insua JT, Giunta D, Ioli P, Villalon R. A registry perspective of hospital discharge costs: pilot results of the 10 most frequent diagnosis and procedures of the Argentine-Health Care Cost and Utilization Project (A-HCUP) Abstracts: A-HCUP. ISPOR. 2011. Value in Health;14 (2011 ):A 1 – A 2 1 4 ; A18.Google Scholar
51. 51.
    •• Degenhardt L, Hall W. The extent of illicit drug use, dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70. Meta-analysis of drug use prevalence with a global perspective.PubMedCrossRefGoogle Scholar
52. 52.
    •• Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–83. Meta-analysis on hepatitis prevalence among IVDU with a global perspective.PubMedCrossRefGoogle Scholar
53. 53.
    Alvarado-Mora MV et al. Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population - how is the epidemiological situation? PLoS One. 2011;6:e18888.PubMedCrossRefGoogle Scholar
54. 54.
    Paraná R, Vitvitski L, Pereira JE. Hepatotropic viruses in the Brazilian Amazon: a health threat. Braz J Infect Dis. 2008;12(3):253–6.PubMedCrossRefGoogle Scholar
55. 55.
    Almeida D, Tavares-Neto J, Vitvitski L, Almeida A, Mello C, Santana D, et al. Serological markers of hepatitis A, B and C viruses in rural communities of the semiarid Brazilian Northeast. Braz J Infect Dis. 2006;10(5):317–21.PubMedCrossRefGoogle Scholar
56. 56.
    Davis P. Health care as a risk factor. CMAJ. 2004;170(11). doi: 10.1503/cmaj.1040690.
57. 57.
    Jha A et al. Patient safety research: an overview of the global evidence. Qual Saf Health Care. 2010;19(1):42–7.PubMedCrossRefGoogle Scholar
58. 58.
    World Health Organization. World Alliance for Patient Safety. Research Priority Setting Working Group. Summary of the evidence on patient safety: Implications for research. Edited by Ashish Jha. 2008.Google Scholar
59. 59.
    Batash S, Khaykis I, Raicht RF, et al. High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. Am J Gastroenterol. 2008;103:922–7.PubMedCrossRefGoogle Scholar
60. 60.
    •• Aranaz-Andrés JM, Aibar-Remón C, Limón-Ramírez R, Amarilla A, Restrepo FR, Urroz O, et al. Prevalence of adverse events in the hospitals of five Latin American countries: results of the ‘Iberoamerican study of adverse events’ (IBEAS). BMJ Qual Saf. 2011;20(12):1043–51. Landmark study for LAC proving health care adverse events in hospitals, regional study, prevalence-incidence.PubMedCrossRefGoogle Scholar
61. 61.
    Rosenthal VD, Maki DG, Graves N. The International Nosocomial Infection Control Consortium (INICC): Goals and objectives, description of surveillance methods, and operational activities. AJIC: American Journal of Infection Control - November 2008 (Vol. 36, Issue 9, Pages e1-e12).Google Scholar
62. 62.
    Rosenthal VD, Maki DG, Salomao R, CÁ M, Mehta Y, Higuera F, et al. International Nosocomial Infection Control Consortium. Device-Associated Nosocomial Infections in 55 Intensive Care Units of 8 Developing Countries. Ann Intern Med. 2006;145(8):582–91.PubMedCrossRefGoogle Scholar
63. 63.
    •• Perz JF, Grytdal S, Beck S, Fireteanu AM, Poissant T, Rizzo E, et al. Case-control study of hepatitis B and hepatitis C in older adults: do healthcare exposures contribute to burden of new infections? Hepatology. 2013;Recent study on Hepatitis C and B among elders in USA, shows HCS risk and USA perspective:917–24. Recent study on Hepatitis C and B among elders in USA, shows HCS risk and USA perspective.CrossRefGoogle Scholar
64. 64.
    Wilburn SQ, Eijkemans G. Preventing needlestick injuries among healthcare workers: a WHO–ICN Collaboration. Intl J Occup Med Environm Med. 2004;10:451–6.Google Scholar
65. 65.
    Ch.60: Occupational medicine. Jamison DT, Breman JG, Measham AR, et al., editors. Disease control priorities in developing countries. 2nd edition. Washington (DC): World Bank; 2006.Google Scholar
66. 66.
    Bosques-Padilla FJ, Vázquez-Elizondo G, Villaseñor-Todd A, Garza-González E, González-González JA, Maldonado-Garza HJ. Hepatitis C viral infection in health care facilities: medical and ethical implications. Ann Hepatol. 2010;9(1):S132–40.Google Scholar
67. 67.
    Pruss-Ustun A, Rapiti E, Hutin Y. Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med. 2005;48:482–90.PubMedCrossRefGoogle Scholar
68. 68.
    Rapiti E, Prüss-Üstün A, Hutin Y. Sharps injuries: assessing the burden of disease from sharps injuries to health-care workers at national and local levels. Environmental Burden of Disease Series, No. 11; World Health Organization Protection of the Human Environment, Geneva, 2005.Google Scholar
69. 69.
    Prüss-Üstün A, Rapiti E, Hutin Y. Sharps injuries: global burden of disease from sharps injuries to health-care workers. Geneva, World Health Organization (WHO Environmental Burden of Disease Series, No. 3). 2003.Google Scholar
70. 70.
    Warley E, Desse J, Szyld E, Silva Nieto F, Cetani S, Pereyra N, et al. Exposición ocupacional al virus de hepatitis C. Medicina (B. Aires) [online]. 2006, vol.66, n.2 [citado 2013-07-18], pp. 97–100 .Google Scholar
71. 71.
    Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut. 1996;38 suppl 2:S48–55.PubMedCrossRefGoogle Scholar
72. 72.
    Frider B, Sookoian S, Castagno G, et al. Prevalence of hepatitis C in health care workers investigated by 2nd generation enzyme-linked and line immunoassays. Acta Gastroenterol Latinoam. 1994;24:71–5.PubMedGoogle Scholar
73. 73.
    • Doddaiah V, Janakiram K, Javagal S. Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Healthcare Workers - AIMS, B G Nagara. American Journal of Life Sciences. 2013;1(4):145–9. Provides references and updated data with LMIC perspective on HCW risks. No LAC data.Google Scholar
74. 74.
    • Kim JY, Cho J, Hwang SH, Kil H, Bae SH, Kim YS, et al. Behavioral and healthcare-associated risk factors for chronic hepatitis C virus infection in Korea. J Korean Med Sci. 2012;27(11):1371–7. Provides insights of behavioral and health care risks and references.PubMedCrossRefGoogle Scholar
75. 75.
    Carballo M, Cody R, O’Reilly E. Migration, hepatitis B and hepatitis C. International Centre for Migration, Health and Development. Background paper for the Hepatitis B and C Summit Conference in Brussels, 14 and 15 October 2010. http://www.hepbcppa.org/wp-content/uploads/2011/11/Migration-report.pdf.
76. 76.
    Lee R. Occupational transmission of bloodborne diseases to healthcare workers in developing countries: meeting the challenges Journal of Hospital Infection - August 2009 (Vol. 72, Issue 4, p. 285–91, Doi: 10.1016/j.jhin.2009.03.016).
77. 77.
    •• Reid S. Estimating the burden of disease from unsafe injections in India: a cost–benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence. Indian J Community Med. 2012;37(2):89–94. Recent review and data synthesis of injections in the community burden in India.PubMedGoogle Scholar
78. 78.
    Kane A, Lloyd J, Zaffran M, Kane M. Transmission of hepatitis B, hepatitis C and Human Inmunodeficiency viruses through unsafe injections in the developing world: a model-based regional estimates. Bull WHO. 1999;77(10):801–7.PubMedGoogle Scholar
79. 79.
    Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ. 1999;6(10):789–800.Google Scholar
80. 80.
    Hutin YJF, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ. 2003;327:1075.PubMedCrossRefGoogle Scholar
81. 81.
    Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS. 2004;15:7–16.PubMedCrossRefGoogle Scholar
82. 82.
    Janszen E, et al., editors. Injections: more expensive, more effective and faster. A report from Equator. In: The impact of injections on daily medical practice. Amsterdam, VU University Press, 1993:43–56.Google Scholar
83. 83.
    Kotwal A. Innovation, diffusion and safety of a medical technology: a review of the literature on injection practices. Soc Sci Med. 2005;60:1133–47.PubMedCrossRefGoogle Scholar
84. 84.
    Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int. 2004;19(1):95–103. doi: 10.1093/heapro/dah11.PubMedCrossRefGoogle Scholar
85. 85.
    Reeler AV. Anthropological perspectives on injections: a review. Bull WHO. 2000;78:135–43.PubMedGoogle Scholar
86. 86.
    Pasha O, Luby SP, Khan AJ, Shah SA, McCormik JB, Fisher - Hochs SP. Household members of hepatitis C virus-infected people in Hazabad, Pakistan : infection by injections from health care providers. Epidemiol Infect. 1999;123:515–8.PubMedCrossRefGoogle Scholar
87. 87.
    Luby S et al. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect. 1997;119:349–56.PubMedCrossRefGoogle Scholar
88. 88.
    Picchio GR, Bare PC, Descalzi VI, et al. High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina. Liver Int. 2006;26:660–5.PubMedCrossRefGoogle Scholar
89. 89.
    • Altaf A, Shah SA, Shaikh K, Constable FM, Khamassi S. Lessons learned from a community based intervention to improve injection safety in Pakistan. BMC Res Notes. 2013;6:159. doi: 10.1186/1756-0500-6-159. Provides access to injection safety, perspective on action for prevention.PubMedCrossRefGoogle Scholar